Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

67.72 -1.23 (-1.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu. 
Via MarketBeat
Topics ETFs
AstraZeneca’s H1 and Q2 2024 Financial Results
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
From AstraZeneca
Via Business Wire
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
From AstraZeneca
Via Business Wire
Cellectis Reports Financial Results for First Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
From AstraZeneca
Via Business Wire
AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​
From AstraZeneca
Via Business Wire
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
From AstraZeneca
Via Business Wire
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
From AstraZeneca
Via Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
From AstraZeneca
Via Business Wire
Q1 2024 results
From AstraZeneca
Via Business Wire
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
From AstraZeneca
Via Business Wire
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.